DAIICHI SANKYO joins the IFPMA
Membership in the world pharmaceutical association is designed to further the company’s internationalisation
Munich, June 25th, 2008 – DAIICHI SANKYO, Co. Ltd., one of Japan’s leading pharmaceutical companies, has taken another step in its international expansion by joining a major pharmaceutical association:
The company is the latest member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), arguably the most important federation in the pharmaceutical industry around the world. Most leading research-based pharmaceutical companies are part of the global federation, as are a number of national pharmaceutical associations.
“If we want to achieve our goal of becoming one of Europe’s leading pharmaceutical companies by 2015 and of generating 70 percent of our turnover outside Japan, we must become active in international interest groups,” said Reinhard Bauer, the CEO of DAIICHI SANKYO EUROPE. “After all, there is hardly any other sector whose success is so closely linked to political factors as the pharmaceutical industry. The trend will grow in the future.”
By joining the IFPMA, DAIICHI SANKYO expects to gain support and information about political activities in the world’s many health-care markets. “We need a paradigm shift,” Bauer said. “Political leaders must stop viewing the health-care sector as just a cost factor. Rather, they must realize that it is also one of the economy’s largest growth engines.” As a member of the IFPMA, the company will work to bring about this paradigm shift, he added.
CONTACT
Dr. Thomas Portz
Corporate Communications
Phone +49(0)89/78 08-468
thomas.portz@daiichi-sankyo.eu
Olaf Lamberz
Corporate Communications
Phone +49(0)89/78 08-442
olaf.lamberz@daiichi-sankyo.eu
Forward-looking statements
This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO EUROPE GmbH. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO EUROPE GmbH assumes no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.
